clinical trial · NCT01522183
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Alexion Pharmaceuticals, Inc.·—·recruiting·n = 3,000
Atypical Hemolytic-Uremic Syndrome
brief summary
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
started
Mar 18, 2013
primary completion
Jan 1, 2031
completion
Jan 1, 2031
last updated
Sep 16, 2025
detailed description
The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients.
official title
An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol